News

The National Institutes of Health (NIH) grant was made under the National Institute for Allergy and Infectious Disease (NIAID) program entitled “cooperative research for the development of vaccines,

Net loss for the 2004 fourth quarter was $1,764.3 million compared with net income of $335.3 million in the prior year. The 2004 fourth quarter included a charge

The guidelines state that Valcyte (valganciclovir) is the preferred treatment for patients with peripheral lesions that are not immediately sight-threatening. Authors cite ease of administration and lack of

The study found that 85% of Crohn’s patients who had experienced a reduced or loss of response to Remicade (infliximab) – currently the only FDA-approved biologic treatment for

The treatment approach, discovered by scientists at the University of Manitoba and the University of Ottawa, reduces cholesterol and triglycerides by acting on newly discovered targets in the

The first study of CX717 in the US will be a double-blind, placebo-controlled study using positron emission tomography (PET) imaging to determine the response of patients with Alzheimer’s

Under the terms of the agreement, Flamel will receive a cash payment from BMS, as well as recovering rights to data produced in connection with the collaboration, including

Under the terms of the agreement, the parties will collaborate on NRP104 development, manufacturing, marketing and sales in the US. Shire will book the product sales and New

Electronic applications for the rotigotine patch were submitted to both the FDA and the European Medicines Evaluation Agency (EMEA) on September 29, 2004. While the application form was